论文部分内容阅读
Hepatocellular carcinoma (HCC) is the second leadingcause of cancer-related death worldwide. At firstdiagnosis, HCC is multifocal in about 35-40％ of patients(1,2). According to Weste guidelines, the treatmentof multifocal (non-metastatic) HCC is well codified:transplantation is indicated for HCCs within Milan criteria(2-3 nodules ≤30 mm), ablation for non-transplantableHCCs within Milan criteria, and chemoembolizationfor the remaining patients (3).